Headline: New CPT code 0244U identifies a proprietary 257-gene tumor sequencing panel used to guide treatment. Lead: CPT code 0244U designates the Oncotype MAP™ PanCancer Tissue Test, a Proprietary Laboratory Analyses (PLA) code for a 257-gene genomic sequence assay of solid tumor tissue now offered by Exact Sciences. This coding identifies a single-manufacturer test and has implications for laboratory billing, payer coverage decisions, and clinical use of multi-gene tumor profiling.

CPT code 0244U represents a tumor tissue genomic sequencing panel that can inform systemic therapy and other treatment planning across a range of solid-organ malignancies. Because it is a PLA code tied to a single manufacturer, its billing and coverage are evaluated differently than generic molecular tests, making the code important for national payer policy and laboratory contracting.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical purpose, how PLA designation affects coding and billing, coverage posture among major national payers, and benchmarks for utilization and reimbursement where available. The publication also summarizes clinical context for multi-gene solid tumor panels and the practical implications for laboratories, clinicians, and payers.

This national-level summary provides the clinical description, payer landscape, and the policy context surrounding CPT code 0244U for stakeholders engaged with molecular oncology testing.